Vascular dementia (VaD) is the second most common form of dementia after Alzheimer’s disease (AD), and one of the major causes of mental and physical disability in developed countries. As such, the identification and implementation of strategies which prevent the development of the condition or enable improvements in patients with VaD are healthcare objectives of the first order. VaD is now regarded as a combined group of clinical-pathological entities rather than one disease, that is, multiple pathogenic mechanisms and lesion types underlie a cognitive impairment of vascular origin. The clinical diagnosis of VaD is complex and difficult because of the heterogeneous nature of its clinical presentation and progression and the low sensitivity of existing clinical criteria. Moreover, there is growing evidence of the epidemiological significance of mixed forms of dementia, and that ischemic processes may precipitate and exacerbate cognitive impairment in AD. Numerous compounds have been proposed as potentially useful in the treatment of patients with VaD, comprising vasodilatative, antithrombotic, hemorrheological, nootropic, antiserotoninergic and, most recently, antiglutamatergic and cholinergic approaches. In spite of some initially favorable reports based on the use of memantine, donepezil and galantamine, there is as yet no conclusive evidence of a definitive treatment for VaD. Unsatisfactory results from VaD drug trials may be attributed in part to the diversity of the patients included (underlying pathogenic mechanisms, number, type, and location of vascular lesions), and to methodological limitations in the design of the trials (outcome measures, end-points, size, follow-up period). The treatment of modifiable vascular risk factors – hypertension, diabetes mellitus, hypercholesterolemia and heart disease – is an important strategy for the reduction of the risk of dementia, and is likely to slow the progress of cognitive decline.

Keywords:
Neuroprotection of vascular dementia, Vascular dementia, Vascular dementia, treatment, Vascular dementia, prevention
1.
Jorm AF, Korten AE, Henderson AS: The prevalence of dementia: a quantitative integration of the literature. Acta Psychiatr Scand 1987;76:465–479.
2.
Knopman DS, Parisi JE, Boeve BF, Cha RH, Apaydin H, Salviati A, et al: Vascular dementia in a population-based autopsy study. Arch Neurol 2003;60:569–575.
3.
Ikeda M, Hokoishi K, Maki N, Nebu A, Tachibana N, Komori K, et al: Increased prevalence of vascular dementia in Japan: a community-based epidemiological study. Neurology 2001;57:839–844.
4.
Fratiglioni L, Launer LJ, Andersen K, Breteler MM, Copeland JR, Dartigues JF, et al: Incidence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000;54(suppl 5):S10–S15.
5.
Knopman DS, Rocca WA, Cha RH, Edland SD, Kokmen E: Incidence of vascular dementia in Rochester, Minn. 1985–1989. Arch Neurol 2002;59:1605–1610.
6.
Lopez OL, Kuller LH, Fitzpatrick A, Ives D, Becker JT, Beauchamp N: Evaluation of dementia in the cardiovascular health cognition study. Neuroepidemiology 2003;22:1–12.
7.
Erkinjuntti T, Inzitari D, Pantoni L, Wallin A, Scheltens P, Rockwood K, et al: Research criteria for subcortical vascular dementia in clinical trials. J Neural Transm Suppl 2000;59:23–30.
8.
Meguro K, Ishii H, Yamaguchi S, Ishizaki J, Shimada M, Sato M, et al: Prevalence of dementia and dementing diseases in Japan: the Tajiri project. Arch Neurol 2002;59:1109–1114.
9.
Bonin-Guillaume S, Zekry D, Giacobini E, Gold G, Michel JP: The economical impact of dementia. Presse Méd 2005;34:35–41.
10.
Lopez OL, Kuller LH, Becker JT: Diagnosis, risk factors, and treatment of vascular dementia. Curr Neurol Neurosci Rep 2004;4:358–367.
11.
Bowler JV, Hachinski V: Vascular dementia; in Ginsberg MD, Bogousslavsky J (eds): Cerebrovascular Disease. Pathophysiology, Diagnosis and Management. Boston, Blackwell Sciences, 1998, pp 1126–1144.
12.
Pohjasvaara T, Mantyla R, Ylikoski R, Kaste M, Erkinjuntti T: Comparison of different clinical criteria (DSM-III, ADDTC, ICD-10, NINDS-AIREN, DSM-IV) for the diagnosis of vascular dementia. National Institute of Neurological Disorders and Stroke-Association Internationale pour la Recherche et l’Enseignement en Neurosciences. Stroke 2000;31:2952–2957.
13.
Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS): Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Lancet 2001;357:169–175.
14.
Kalaria RN, Ballard C: Overlap between pathology of Alzheimer disease and vascular dementia. Alzheimer Dis Assoc Disord 1999(suppl 3):S115–S123.
15.
Heyman A, Fillenbaum GG, Welsh-Bohmer KA, Gearing M, Mirra SS, Mohs RC, et al: Cerebral infarcts in patients with autopsy-proven Alzheimer’s disease: CERAD. XVIII. Consortium to establish a registry for Alzheimer’s disease. Neurology 1998;51:159–162.
16.
Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, Markesbery WR: Brain infarction and the clinical expression of Alzheimer disease. The Nun study. JAMA 1997;277:813–817.
17.
Bowler JV: Vascular cognitive impairment. Stroke 2004;35:386–388.
18.
Erkinjuntti T, Roman G, Gauthier S, Feldman H, Rockwood K: Emerging therapies for vascular dementia and vascular cognitive impairment. Stroke 2004;35:1010–1017.
19.
O’Brien JT, Erkinjuntti T, Reisberg B, Roman G, Sawada T, Pantoni L, et al: Vascular cognitive impairment. Lancet Neurol 2003;2:89–98.
20.
Hachinski V: Preventable senility: a call for action against the vascular dementias. Lancet 1992;340:645–648.
21.
Hulette C, Nochlin D, McKeel D, Morris JC, Mirra SS, Sumi SM, et al: Clinical-neuropathologic findings in multi-infarct dementia: a report of six autopsied cases. Neurology 1997;48:668–672.
22.
Barba R, Martinez-Espinosa S, Rodriguez-Garcia E, Pondal M, Vivancos J, Del Ser T: Poststroke dementia: clinical features and risk factors. Stroke 2000;31:1494–1501.
23.
Censori B, Manara O, Agostinis C, Camerlingo M, Casto L, Galavotti B, et al: Dementia after first stroke. Stroke 1996;27:1205–1210.
24.
Desmond DW, Moroney JT, Paik MC, Sano M, Mohr JP, Aboumatar S, et al: Frequency and clinical determinants of dementia after ischemic stroke. Neurology 2000;54:1124–1131.
25.
Ballard C, Rowan E, Stephens S, Kalaria R, Kenny RA: Prospective follow-up study between 3 and 15 months after stroke: improvements and decline in cognitive function among dementia-free stroke survivors >75 years of age. Stroke 2003;34:2440–2444.
26.
Kokmen E, Whisnant JP, O’Fallon WM, Chu CP, Beard CM: Dementia after ischemic stroke: a population-based study in Rochester, Minnesota (1960–1984). Neurology 1996;46:154–159.
27.
Fischer P, Gatterer G, Marterer A, Simanyi M, Danielczyk W: Course characteristics in the differentiation of dementia of the Alzheimer type and multi-infarct dementia. Acta Psychiatr Scand 1990;81:551–553.
28.
Chui HC, Mack W, Jackson JE, Mungas D, Reed BR, Tinklenberg J, et al: Clinical criteria for the diagnosis of vascular dementia: a multicenter study of comparability and interrater reliability. Arch Neurol 2000;57:191–196.
29.
Roman GC, Erkinjuntti T, Wallin A, Pantoni L, Chui HC: Subcortical ischaemic vascular dementia. Lancet Neurol 2002;1:426–436.
30.
Brun A: The neuropathology of vascular dementia; in Chiu HC, Gustafson L, Ames D, Folstein MF (eds): Cerebrovascular Disease and Dementia. London, Dunitz, 2000, pp 69–76.
31.
Inzitari D, Erkinjuntti T, Wallin A, Del Ser T, Romanelli M, Pantoni L: Subcortical vascular dementia as a specific target for clinical trials. Ann NY Acad Sci 2000;903:510–521.
32.
Benson DF, Cummings JL: Angular gyrus syndrome simulating Alzheimer’s disease. Arch Neurol 1982;39:616–620.
33.
Looi JC, Sachdev PS: Differentiation of vascular dementia from AD on neuropsychological tests. Neurology 1999;53:670–678.
34.
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, American Psychiatric Press, 1994.
35.
Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al: Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993;43:250–260.
36.
Chui HC, Victoroff JI, Margolin D, Jagust W, Shankle R, Katzman R: Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer’s Disease Diagnostic and Treatment Centers. Neurology 1992;42:473–480.
37.
World Health Organization: The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research. Geneva, WHO, 1993.
38.
Knopman DS, Parisi JE, Boeve BF, Cha RH, Apaydin H, Salviati A, et al: Vascular dementia in a population-based autopsy study. Arch Neurol 2003;60:569–575.
39.
Wetterling T, Kanitz RD, Borgis KJ: Comparison of different diagnostic criteria for vascular dementia (ADDTC, DSM-IV, ICD-10, NINDS-AIREN). Stroke 1996;27:30–36.
40.
Pohjasvaara T, Erkinjuntti T, Vataja R, Kaste M: Dementia three months after stroke. Baseline frequency and effect of different definitions of dementia in the Helsinki Stroke Aging Memory Study (SAM) cohort. Stroke 1997;28:785–792.
41.
Lopez OL, Kuller LH, Becker JT, Jagust WJ, DeKosky ST, Fitzpatrick A, et al: Classification of vascular dementia in the Cardiovascular Health Study Cognition Study. Neurology 2005;64:1539–1547.
42.
Lopez OL, Larumbe MR, Becker JT, Rezek D, Rosen J, Klunk W, et al: Reliability of NINDS-AIREN clinical criteria for the diagnosis of vascular dementia. Neurology 1994;44:1240–1245.
43.
Korczyn AD: The underdiagnosis of the vascular contribution to dementia. J Neurol Sci 2005;229–230:3–6.
44.
Vinters HV, Ellis WG, Zarow C, Zaias BW, Jagust WJ, Mack WJ, et al: Neuropathologic substrates of ischemic vascular dementia. J Neuropathol Exp Neurol 2000;59:931–945.
45.
Zekry D, Duyckaerts C, Belmin J, Geoffre C, Moulias R, Hauw JJ: Alzheimer’s disease and brain infarcts in the elderly. Agreement with neuropathology. J Neurol 2002;249:1529–1534.
46.
Zekry D, Hauw JJ, Gold G: Mixed dementia: epidemiology, diagnosis, and treatment. J Am Geriatr Soc 2002;50:1431–1438.
47.
Langa KM, Foster NL, Larson EB: Mixed dementia: emerging concepts and therapeutic implications. JAMA 2004;292:2901–2908.
48.
Zekry D, Duyckaerts C, Belmin J, Geoffre C, Herrmann F, Moulias R, et al: The vascular lesions in vascular and mixed dementia: the weight of functional neuroanatomy. Neurobiol Aging 2003;24:213–219.
49.
Lim A, Tsuang D, Kukull W, Nochlin D, Leverenz J, McCormick W, et al: Clinico-neuropathological correlation of Alzheimer’s disease in a community-based case series. J Am Geriatr Soc 1999;47:564–569.
50.
Breteler MM: Vascular risk factors for Alzheimer’s disease: an epidemiologic perspective. Neurobiol Aging 2000;21:153–160.
51.
Meyer JS, Rauch GM, Crawford K, Rauch RA, Konno S, Akiyama H, et al: Risk factors accelerating cerebral degenerative changes, cognitive decline and dementia. Int J Geriatr Psychiatry 1999;14:1050–1061.
52.
Esiri MM, Nagy Z, Smith MZ, Barnetson L, Smith AD: Cerebrovascular disease and threshold for dementia in the early stages of Alzheimer’s disease. Lancet 1999;354:919–920.
53.
De la Torre JC: Alzheimer disease as a vascular disorder: nosological evidence. Stroke 2002;33:1152–1162.
54.
Bugiani O: A β-related cerebral amyloid angiopathy. Neurol Sci 2004;25(suppl 1):S1–S2.
55.
Goulding JM, Signorini DF, Chatterjee S, Nicoll JA, Stewart J, Morris R, et al: Inverse relation between Braak stage and cerebrovascular pathology in Alzheimer predominant dementia. J Neurol Neurosurg Psychiatry 1999;67:654–657.
56.
Zekry D, Duyckaerts C, Moulias R, Belmin J, Geoffre C, Herrmann F, et al: Degenerative and vascular lesions of the brain have synergistic effects in dementia of the elderly. Acta Neuropathol (Berl) 2002;103:481–487.
57.
Hachinski V, Munoz D: Vascular factors in cognitive impairment – where are we now? Ann NY Acad Sci 2000;903:1–5.
58.
Pantoni L, Rossi R, Inzitari D, Bianchi C, Beneke M, Erkinjuntti T, et al: Efficacy and safety of nimodipine in subcortical vascular dementia: a subgroup analysis of the Scandinavian Multi-Infarct Dementia Trial. J Neurol Sci 2000;175:124–134.
59.
Pantoni L, Bianchi C, Beneke M, Inzitari D, Wallin A, Erkinjuntti T: The Scandinavian Multi-Infarct Dementia Trial: a double-blind, placebo-controlled trial on nimodipine in multi-infarct dementia. J Neurol Sci 2000;175:116–123.
60.
Pantoni L, Carosi M, Amigoni S, Mascalchi M, Inzitari D: A preliminary open trial with nimodipine in patients with cognitive impairment and leukoaraiosis. Clin Neuropharmacol 1996;19:497–506.
61.
Meyer JS, Rogers RL, McClintic K, Mortel KF, Lotfi J: Randomized clinical trial of daily aspirin therapy in multi-infarct dementia. A pilot study. J Am Geriatr Soc 1989;37:549–555.
62.
Williams PS, Rands G, Orrel M, Spector A: Aspirin for vascular dementia. Cochrane Database Syst Rev 2000(4):CD001296.
63.
Lopez-Pousa S, Mercadal-Dalmau J, Marti-Cuadros AM, Vilalta-Franch J, Lozano-Gallego M: Triflusal in the prevention of vascular dementia. Rev Neurol 1997;25:1525–1528.
64.
Parnetti L, Mari D, Abate G, Balestreri R, Cucinotta D, Coppola R, et al: Vascular dementia Italian sulodexide study (VADISS). Clinical and biological results. Thromb Res 1997;87:225–233.
65.
Adibhatla RM, Hatcher JF, Dempsey RJ: Citicoline: neuroprotective mechanisms in cerebral ischemia. J Neurochem 2002;80:12–23.
66.
Fioravanti M, Yanagi M: Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev 2000(2):CD000269.
67.
Flicker L, Grimley EJ: Piracetam for dementia or cognitive impairment. Cochrane Database Syst Rev 2000(2):CD001011.
68.
Maina G, Fiori L, Torta R, Fagiani MB, Ravizza L, Bonavita E, et al: Oxiracetam in the treatment of primary degenerative and multi-infarct dementia: a double-blind, placebo-controlled study. Neuropsychobiology 1989;21:141–145.
69.
Schneider LS, Olin JT: Overview of clinical trials of hydergine in dementia. Arch Neurol 1994;51:787–798.
70.
Oudart N: Naftidrofuryl inhibits contractions to serotonin in intact and de-endothelialized cerebral arteries in vitro. J Cardiovasc Pharmacol 1990(suppl 3):S45–S48.
71.
Moller HJ, Hartmann A, Kessler C, Rainer M, Brown T, Gamand S, et al: Naftidrofuryl in the treatment of vascular dementia. Eur Arch Psychiatry Clin Neurosci 2001;251:247–254.
72.
Emeriau JP, Lehert P, Mosnier M: Efficacy of naftidrofuryl in patients with vascular or mixed dementia: results of a multicenter, double-blind trial. Clin Ther 2000;22:834–844.
73.
Parnetti L, Ambrosoli L, Agliati G, Caratozzolo P, Fossati L, Frattola L, et al: Posatirelin in the treatment of vascular dementia: a double-blind multicentre study vs. placebo. Acta Neurol Scand 1996;93:456–463.
74.
Le Bars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF: A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. JAMA 1997;278:1327–1332.
75.
Kanowski S, Hoerr R: Ginkgo biloba extract EGb 761 in dementia: intent-to-treat analyses of a 24-week, multi-center, double-blind, placebo-controlled, randomized trial. Pharmacopsychiatry 2003;36:297–303.
76.
Van Dongen MC, van Rossum E, Kessels AG, Sielhorst HJ, Knipschild PG: The efficacy of Ginkgo for elderly people with dementia and age-associated memory impairment: new results of a randomized clinical trial. J Am Geriatr Soc 2000;48:1183–1194.
77.
Herrmann WM, Stephan K, Gaede K, Apeceche M: A multicenter randomized double-blind study on the efficacy and safety of nicergoline in patients with multi-infarct dementia. Dement Geriatr Cogn Disord 1997;8:9–17.
78.
Bes A, Orgogozo JM, Poncet M, Rancurel G, Weber M, Bertholom N, et al: A 24-month, double-blind, placebo-controlled multicentre pilot study of the efficacy and safety of nicergoline 60 mg/day in elderly hypertensive patients with leukoaraiosis. Eur J Neurol 1999;6:313–322.
79.
Fioravanti M, Flicker L: Efficacy of nicergoline in dementia and other age associated forms of cognitive impairment. Cochrane Database Syst Rev 2001(4):CD003159.
80.
Tomimoto H, Akiguchi I, Ohtani R, Yagi H, Ogura S, Wakita H: Effects of an antithrombin drug in patients with subacute exacerbations of Binswanger disease. Intern Med 2000;39:966–969.
81.
Schuff-Werner P, Schutz E, Seyde WC, Eisenhauer T, Janning G, Armstrong VW, et al: Improved haemorheology associated with a reduction in plasma fibrinogen and LDL in patients being treated by heparin-induced extracorporeal LDL precipitation (HELP). Eur J Clin Invest 1989;19:30–37.
82.
Walzl M: A promising approach to the treatment of multi-infarct dementia. Neurobiol Aging 2000;21:283–287.
83.
European Pentoxifylline Multi-Infarct Dementia Study. Eur Neurol 1996;36:315–321.
84.
Black RS, Barclay LL, Nolan KA, Thaler HT, Hardiman ST, Blass JP: Pentoxifylline in cerebrovascular dementia. J Am Geriatr Soc 1992;40:237–244.
85.
Kittner B: Clinical trials of propentofylline in vascular dementia. European/Canadian Propentofylline Study Group. Alzheimer Dis Assoc Disord 1999;13(suppl 3):S166–S171.
86.
Rother M, Erkinjuntti T, Roessner M, Kittner B, Marcusson J, Karlsson I: Propentofylline in the treatment of Alzheimer’s disease and vascular dementia: a review of phase III trials. Dement Geriatr Cogn Disord 1998;9(suppl 1): 36–43.
87.
Orgogozo JM, Rigaud AS, Stoffler A, Mobius HJ, Forette F: Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke 2002;33:1834–1839.
88.
Wilcock G, Mobius HJ, Stoffler A: A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol 2002;17:297–305.
89.
Mobius HJ, Stoffler A: New approaches to clinical trials in vascular dementia: memantine in small vessel disease. Cerebrovasc Dis 2002(suppl 2):61–66.
90.
Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV: Efficacy of galantamine in probable vascular dementia and Alzheimer’s disease combined with cerebrovascular disease: a randomised trial. Lancet 2002;359:1283–1290.
91.
McKeith I: Galantamine for vascular dementia. Lancet Neurol 2002;1:210.
92.
Erkinjuntti T, Kurz A, Small GW, Bullock R, Lilienfeld S, Damaraju CV: An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia. Clin Ther 2003;25:1765–1782.
93.
Moretti R, Torre P, Antonello RM, Cazzato G: Rivastigmine in subcortical vascular dementia: a comparison trial on efficacy and tolerability for 12 months follow-up. Eur J Neurol 2001;8:361–362.
94.
Moretti R, Torre P, Antonello RM, Cazzato G, Bava A: Rivastigmine in subcortical vascular dementia: an open 22-month study. J Neurol Sci 2002;203–204:141–146.
95.
Wilkinson D, Doody R, Helme R, Taubman K, Mintzer J, Kertesz A, et al: Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology 2003;61:479–486.
96.
Black S, Roman GC, Geldmacher DS, Salloway S, Hecker J, Burns A, et al: Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 2003;34:2323–2330.
97.
Schneider LS: Cholinesterase inhibitors for vascular dementia? Lancet Neurol 2003;2:658–659.
98.
Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, et al: Midlife vascular risk factors and Alzheimer’s disease in later life: longitudinal, population-based study. BMJ 2001;322:1447–1451.
99.
Haan MN, Wallace R: Can dementia be prevented? Brain aging in a population-based context. Annu Rev Public Health 2004;25:1–24.
100.
Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA: Statins and the risk of dementia. Lancet 2000;356:1627–1631.
101.
Birkenhager WH, Forette F, Seux ML, Wang JG, Staessen JA: Blood pressure, cognitive functions, and prevention of dementias in older patients with hypertension. Arch Intern Med 2001;161:152–156.
102.
Ritchie K, Lovestone S. The dementias. Lancet 2002;360:1759–1766.
103.
Pohjasvaara T, Erkinjuntti T, Ylikoski R, Hietanen M, Vataja R, Kaste M: Clinical determinants of poststroke dementia. Stroke 1998;29:75–81.
104.
Moroney JT, Bagiella E, Desmond DW, Paik MC, Stern Y, Tatemichi TK: Risk factors for incident dementia after stroke. Role of hypoxic and ischemic disorders. Stroke 1996;27:1283–1289.
105.
Bornstein NM, Gur AY, Treves TA, Reider-Groswasser I, Aronovich BD, Klimovitzky SS, et al: Do silent brain infarctions predict the development of dementia after first ischemic stroke? Stroke 1996;27:904–905.
106.
Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM: Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 2003;348:1215–1222.
107.
De Groot JC, De Leeuw FE, Oudkerk M, Van Gijn J, Hofman A, Jolles J, et al: Periventricular cerebral white matter lesions predict rate of cognitive decline. Ann Neurol 2002;52:335–341.
108.
Longstreth WT Jr, Bernick C, Manolio TA, Bryan N, Jungreis CA, Price TR: Lacunar infarcts defined by magnetic resonance imaging of 3660 elderly people: the Cardiovascular Health Study. Arch Neurol 1998;55:1217–1225.
109.
Schmidt R, Schmidt H, Fazekas F: Vascular risk factors in dementia. J Neurol 2000;247:81–87.
110.
Hack W, Kaste M, Bogousslavsky J, Brainin M, Chamorro A, Lees K, et al: European Stroke Initiative Recommendations for Stroke Management – Update 2003. Cerebrovasc Dis 2003;16:311–337.
111.
Kilander L, Nyman H, Boberg M, Hansson L, Lithell H: Hypertension is related to cognitive impairment: a 20-year follow-up of 999 men. Hypertension 1998;31:780–786.
112.
Launer LJ, Masaki K, Petrovitch H, Foley D, Havlik RJ: The association between midlife blood pressure levels and late-life cognitive function. The Honolulu-Asia Aging Study. JAMA 1995;274:1846–1851.
113.
Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, et al: 15-year longitudinal study of blood pressure and dementia. Lancet 1996;347:1141–1145.
114.
Skoog I: Risk factors for vascular dementia: a review. Dementia 1994;5:137–144.
115.
Hebert R, Lindsay J, Verreault R, Rockwood K, Hill G, Dubois MF: Vascular dementia: incidence and risk factors in the Canadian study of health and aging. Stroke 2000;31:1487–1493.
116.
Glynn RJ, Beckett LA, Hebert LE, Morris MC, Scherr PA, Evans DA: Current and remote blood pressure and cognitive decline. JAMA 1999;281:438–445.
117.
Murray MD, Lane KA, Gao S, Evans RM, Unverzagt FW, Hall KS, et al: Preservation of cognitive function with antihypertensive medications: a longitudinal analysis of a community-based sample of African-Americans. Arch Intern Med 2002;162:2090–2096.
118.
Knopman D, Boland LL, Mosley T, Howard G, Liao D, Szklo M, et al: Cardiovascular risk factors and cognitive decline in middle-aged adults. Neurology 2001;56:42–48.
119.
Forette F, Seux ML, Staessen JA, Thijs L, Birkenhager WH, Babarskiene MR, et al: Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998;352:1347–1351.
120.
Forette F, Seux ML, Staessen JA, Thijs L, Babarskiene MR, Babeanu S, et al: The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 2002;162:2046–2052.
121.
Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al: The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003;21:875–886.
122.
Tzourio C, Anderson C, Chapman N, Woodward M, Neal B, MacMahon S, et al: Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 2003;163:1069–1075.
123.
Reitz C, Tang MX, Luchsinger J, Mayeux R: Relation of plasma lipids to Alzheimer disease and vascular dementia. Arch Neurol 2004;61:705–714.
124.
Dufouil C, Richard F, Fievet N, Dartigues JF, Ritchie K, Tzourio C, et al: APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: the Three-City Study. Neurology 2005;64:1531–1538.
125.
Yaffe K, Barrett-Connor E, Lin F, Grady D: Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol 2002;59:378–384.
126.
Moroney JT, Tang MX, Berglund L, Small S, Merchant C, Bell K, et al: Low-density lipoprotein cholesterol and the risk of dementia with stroke. JAMA 1999;282:254–260.
127.
Fried LP, Borhani NO, Enright P, Furberg CD, Gardin JM, Kronmal RA, et al: The Cardiovascular Health Study: design and rationale. Ann Epidemiol 1991;1:263–276.
128.
Gengo F, Cwudzinski D, Kinkel P, Block G, Stauffer L, Lines C: Effects of treatment with lovastatin and pravastatin on daytime cognitive performance. Clin Cardiol 1995;18:209–214.
129.
Rea TD, Breitner JC, Psaty BM, Fitzpatrick AL, Lopez OL, Newman AB, et al: Statin use and the risk of incident dementia: the Cardiovascular Health Study. Arch Neurol 2005;62:1047–1051.
130.
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7–22.
131.
Collins R, Armitage J, Parish S, Sleight P, Peto R: Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20,536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004;363:757–767.
132.
Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, et al: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623–1630.
133.
Suribhatla S, Dennis MS, Potter JF: A study of statin use in the prevention of cognitive impairment of vascular origin in the UK. J Neurol Sci 2005;229–230:147–150.
134.
Hassing LB, Johansson B, Nilsson SE, Berg S, Pedersen NL, Gatz M, et al: Diabetes mellitus is a risk factor for vascular dementia, but not for Alzheimer’s disease: a population-based study of the oldest old. Int Psychogeriatr 2002;14:239–248.
135.
Guo Z, Viitanen M, Fratiglioni L, Winblad B: Low blood pressure and dementia in elderly people: the Kungsholmen Project. BMJ 1996;312:805–808.
136.
Zuccala G, Onder G, Pedone C, Carosella L, Pahor M, Bernabei R, et al: Hypotension and cognitive impairment: selective association in patients with heart failure. Neurology 2001;57:1986–1992.
137.
Ryglewicz D, Rodo M, Kunicki PK, Bednarska-Makaruk M, Graban A, Lojkowska W, et al: Plasma antioxidant activity and vascular dementia. J Neurol Sci 2002;203–204:195–197.
138.
Masaki KH, Losonczy KG, Izmirlian G, Foley DJ, Ross GW, Petrovitch H, et al: Association of vitamin E and C supplement use with cognitive function and dementia in elderly men. Neurology 2000;54:1265–1272.
139.
Sobrado M, Roda JM, Lopez MG, Egea J, Garcia AG: Galantamine and memantine produce different degrees of neuroprotection in rat hippocampal slices subjected to oxygen-glucose deprivation. Neurosci Lett 2004;365:132–136.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.